Who pays for weight-loss drugs? The coverage map is splitting in two
For most people the hardest question about GLP-1 medicines is not which one works best. It is whether anyone will pay for it. A month of treatment carries a list price in the region of 245 dollars in the United States, and for a therapy that is meant to be taken for years, that number decides everything. This month two things happened that point in opposite directions, and together they explain why your neighbour in the next state may have a completely different answer than you do.
The first is expansion. Indiana confirmed that its Medicaid programme will cover GLP-1 medicines for obesity through a federal initiative called the BALANCE model. Under the arrangement the state pays roughly 85 dollars per patient per month, with the rest covered by federal contributions and discounts negotiated with the manufacturers, who have also agreed to provide lifestyle support services alongside the medication. The important detail for anyone waiting on this: the state has not yet published who qualifies or when coverage actually begins, because the agreement is still being finalised. An announcement is not a prescription.
The second is contraction. At the start of 2026 only thirteen state Medicaid programmes covered GLP-1 medicines for obesity, down from sixteen the year before. States including California, New Hampshire, Pennsylvania and South Carolina removed coverage, and the reason given was almost always the same: the budget could not carry it. So while one state was joining a federal model, others were stepping back from paying alone.
These two movements are not a contradiction. They are the same economic fact seen from two sides. At full list price, a state Medicaid programme covering a large obese population faces a bill it cannot absorb, which is why coverage collapses when a state acts on its own. The federal model works by lowering the net price through negotiated discounts, which brings the monthly cost down to a level a state budget can survive. The result is a coverage map that increasingly splits between states inside such an arrangement and states outside it, rather than a single national answer.
The same squeeze is visible in the private market, just in a different place. Hims & Hers, the telehealth company, reported this month that its revenue grew 38 percent to around 753 million dollars in a single quarter, yet it still posted a loss far worse than analysts expected. The cause was its move from cheaper compounded copies to branded GLP-1 medicines: gross margin fell from 76 percent to 64 percent. Someone always absorbs the difference between what a drug costs and what a patient can pay. In Medicaid it is the taxpayer and the manufacturer discount; in telehealth it is the intermediary's margin.
What does this mean in practice? Do not take a national headline as an answer about your own situation. Coverage in the United States is decided state by state and plan by plan, so the only reliable step is to check your specific plan's current formulary and ask what prior authorisation it requires, since even covered medicines usually need documented criteria before approval. If you live somewhere that recently dropped coverage, ask your prescriber about manufacturer patient-support programmes, which are separate from insurance and have their own eligibility rules. And if your state has just joined a new model, expect a delay between the press release and the pharmacy counter. This is general information, not medical or financial advice.